Partnership with drug manufacturer seeks to provide relief for men with advanced prostate cancer. Prostate cancer patients are set to access a crucial drug used to manage the condition after the National Hospital Insurance Fund unveiled a partnership with the manufacturer. Prostate cancer develops in the prostate gland located at the base of the bladder, when prostate cells multiply abnormally and uncontrollably. This would mean that accounting for drugs alone, the limit for the prostate cancer patient would run out in six months. Prostate cancer is the fourth commonest cancer in Kenya, accounting for six per cent of cancer cases and 15 per cent of new cancer cases in men.

Source: Daily Nation February 19, 2019 06:00 UTC